- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
IntelGenx Announces Decisions in Suboxone Patent Litigation
IntelGenx shared the decision placed by the Delaware Court in which the process used to manufacture an opiate addiction treatment does not infringe the patent of MonoSol Rx.
IntelGenx (TSXV:IGX; OTCQX:IGXT) shared the decision placed by the Delaware Court in which the process used to manufacture an opiate addiction treatment does not infringe the patent of MonoSol Rx.
As quoted in the press release:
“This is a great outcome for IntelGenx, confirming that our process for making generic Suboxone® film does not infringe the process covered by the ‘497 patent’,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx.
Also on August 31, 2017, the Delaware Court rendered a decision in a separate case, which previously resulted in a finding infringement of the MonoSol Rx U.S. Patent No 8,603,514 (the “514 patent”), denying IntelGenx’ and Par’s motion to reopen the case.
Dr. Zerbe further commented, “According to IMS data, the oral film market for opioid dependence in the United States was worth more than $1.4 billion in 2014. We are working with Par on the appeal process.”
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.